These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35356872)

  • 1. Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer's perspective.
    Forster A; Junger M
    Hum Vaccin Immunother; 2022 Nov; 18(4):2050123. PubMed ID: 35356872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.
    Hacker E; Baker B; Lake T; Ross C; Cox M; Davies C; Skinner SR; Booy R; Forster A
    Vaccine; 2023 Sep; 41(41):5925-5930. PubMed ID: 37643926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial.
    Depelsenaire ACI; Witham K; Veitch M; Wells JW; Anderson CD; Lickliter JD; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP; Forster AH
    PLoS One; 2021; 16(7):e0255282. PubMed ID: 34329337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study.
    Baker B; Hacker E; Siller G; Lee M; Mursaliyev N; Forster A
    Hum Vaccin Immunother; 2023 Dec; 19(1):2189409. PubMed ID: 36949009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray patches: scratching the surface of vaccine delivery.
    Choo JJY; McMillan CLD; Young PR; Muller DA
    Expert Rev Vaccines; 2023; 22(1):937-955. PubMed ID: 37846657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.
    ; Ampofo WK; Baylor N; Cobey S; Cox NJ; Daves S; Edwards S; Ferguson N; Grohmann G; Hay A; Katz J; Kullabutr K; Lambert L; Levandowski R; Mishra AC; Monto A; Siqueira M; Tashiro M; Waddell AL; Wairagkar N; Wood J; Zambon M; Zhang W
    Influenza Other Respir Viruses; 2012 Mar; 6(2):142-52, e1-5. PubMed ID: 21819547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usability, acceptability, and feasibility of a High-Density Microarray Patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings.
    Davies C; Taba M; Deng L; Karatas C; Bag S; Ross C; Forster A; Booy R; Skinner SR
    Hum Vaccin Immunother; 2022 Nov; 18(4):2018863. PubMed ID: 35100525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.
    Abelin A; Colegate T; Gardner S; Hehme N; Palache A
    Vaccine; 2011 Feb; 29(6):1135-8. PubMed ID: 21115061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.
    Ramezanpour B; Pronker ES; Kreijtz JH; Osterhaus AD; Claassen E
    Vaccine; 2015 Aug; 33(35):4349-58. PubMed ID: 26048779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
    Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
    Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving pandemic preparedness through better, faster influenza vaccines.
    Newland M; Durham D; Asher J; Treanor JJ; Seals J; Donis RO; Johnson RA
    Expert Rev Vaccines; 2021 Mar; 20(3):235-242. PubMed ID: 33576708
    [No Abstract]   [Full Text] [Related]  

  • 13. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
    Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB
    Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study.
    Simpson CR; Lone N; McMenamin J; Gunson R; Robertson C; Ritchie LD; Sheikh A
    Health Technol Assess; 2015 Oct; 19(79):1-32. PubMed ID: 26450686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities.
    Scarnà T; Menozzi-Arnaud M; Friede M; DeMarco K; Plopper G; Hamer M; Chakrabarti A; Gilbert PA; Jarrahian C; Mistilis J; Hesselink R; Gandrup-Marino K; Amorij JP; Giersing B
    Expert Opin Drug Deliv; 2023 Mar; 20(3):315-322. PubMed ID: 36649573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming the vaccine supply chain in Australia: Opportunities and challenges.
    Bozorgi A; Fahimnia B
    Vaccine; 2021 Oct; 39(41):6157-6165. PubMed ID: 34489129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.
    Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I
    Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptance of a vaccine against pandemic influenza A (H1N1) virus amongst healthcare workers in Beijing, China.
    Seale H; Kaur R; Wang Q; Yang P; Zhang Y; Wang X; Li X; Zhang H; Zhang Z; MacIntyre CR
    Vaccine; 2011 Feb; 29(8):1605-10. PubMed ID: 21211593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges.
    Hessel L;
    Influenza Other Respir Viruses; 2009 Jul; 3(4):165-70. PubMed ID: 19627373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing pandemic influenza vaccination of healthcare workers--a systematic review.
    Prematunge C; Corace K; McCarthy A; Nair RC; Pugsley R; Garber G
    Vaccine; 2012 Jul; 30(32):4733-43. PubMed ID: 22643216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.